<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'>This page presents a summary of all clinical variables and includes explanations for each abbreviation.&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'>&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>SampleType:</strong> Can vary between cutaneous metastasis (CM), distant metastasis (DM),lymph node metastasis (LN),local recurrence (LR), non-tumor (NT), primary tumor (PT), tumor microenvironment (TM)&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Age:</strong> Refers to the age of the patient at the time of diagnosis&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Sex:</strong> Refers to the sex of the patient&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>AJCC8_stage:</strong> Tumor stage based on American Joint Committee on Cancer (AJCC) staging&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>MelanomaSubType:</strong> Refers to the histological subtype of melanoma: superficial spreading melanoma (SSM), nodular melanoma (NM), and acral lentiginous melanoma (ALM)&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Clark_level:</strong> The Clark Level is a classification system used to describe the depth of melanoma infiltration within the layers of the skin. Varies between L1 and L5&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>BRAFstatus</strong>: BRAF mutation status&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Breslow_stage:</strong> Staging based on Breslow thickness&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Tumor_content:</strong> The percentage of tumor cells observed on the slide by the pathologist</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>PFS(months):&nbsp;</strong>Progression-free survival&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>OS(months):</strong> Overall survival&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Breslow_thickness:</strong> The Breslow thickness measures the vertical thickness of a melanoma lesion.&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>stage:</strong> Staging based on TNM classification&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>NRAS:</strong> NRAS mutation status&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>DistMetLocation:</strong> Distant metastasis location&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>OS_DAYS:</strong> Overall survival in days&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>cKIT:</strong> cKIT mutation status&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Origin:</strong> Origin of metastatic site in the Tercero study&nbsp;</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>OS.months:</strong> Overall survival in months</p>
<p style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Aptos",sans-serif;'><strong>Primary_localization:</strong> Localization of the primary tumor</p>